• Dr. López Martín is a medical oncologist with more than 20 years of clinical experience in healthcare and research in some of Spain’s leading hospitals and in the biopharmaceutical sector

• He joins the Atrys team with the aim of supporting and promoting the oncology and diagnostics business lines, with the short-term priorities of developing a clinical and translational research programme and optimising data-driven clinical decision support strategies

Atrys Health, compañía healthtech global que presta servicios de prevención, diagnóstico y tratamiento médico de precisión, pionera en telemedicina y tratamiento oncológico sigue creciendo e impulsando sus áreas de especialización. Con el compromiso de reforzar los servicios de diagnóstico y tratamiento oncológico, Atrys ha incorporado a José Antonio López Martín, oncólogo médico con amplia experiencia en el ámbito asistencial y de la investigación, como nuevo director médico del área de Medicina de Precisión.

With more than 20 years of clinical experience in university hospitals, López Martín is a specialist in Medical Oncology at the Hospital Universitario San Carlos (Madrid). He holds a PhD in Medicine from the Complutense University of Madrid and has completed postgraduate master’s degrees in Molecular Biology of Cancer at the European School of Oncology and in Bioinformatics and Computational Biology at the National School of Health. Throughout his career he has held the position of assistant doctor in the Medical Oncology Service of the Hospital 12 de Octubre (Madrid) between 2007 and 2021. In this position he was responsible for the care of patients with melanoma, sarcomas or tumours refractory to standard treatments, as well as clinical and translational research in these pathologies.

He was also one of the promoters of the creation and certification of the Early Phase Clinical Trials Unit in Oncology, and of the Translational Oncology laboratory, within the Instituto de Investigación Sanitaria Hospital 12 de Octubre. In this laboratory, he co-led research projects on biomarkers and mechanisms of action and drug resistance, as well as on immuno-inflammatory responses associated with cancer.

In parallel, Dr. López Martín has participated as a researcher in multiple clinical trials for the pharmaceutical industry, as well as in independent clinical studies, and is a visiting researcher in projects at the Bioinformatics Unit of the Spanish National Cancer Research Centre (CNIO). In 2014 he co-founded the Spanish Group for Immuno-Biological Therapies in Cancer (GÉTICA), of which he was president until 2021. He has also served as Medical Director of Oncology and Associate Director of Virology Strategic Development at PharmaMar.

In the educational field, he teaches on the Master’s Degree in Musculoskeletal Tumours (Universidad Europea de Madrid) and on the Master’s Degree in Bioinformatics and Data Science in Personalised Precision Medicine and Health (Escuela Nacional de Sanidad-Instituto de Salud Carlos III).

The Precision Medicine area is one of the company’s strategic pillars, comprising all diagnostic activity – telemedicine, nuclear medicine, pathological and molecular anatomy – and oncology treatment – medical oncology and advanced radiotherapy. At Atrys Health, Dr. López Martín will be in charge of developing a clinical and translational research programme, as well as optimising data-driven clinical decision support strategies.

According to Isabel Lozano, CEO of Atrys, ‘The addition of Dr. López Martín as Medical Director of Precision Medicine at Atrys reflects the company’s strong commitment to ensuring precision oncology diagnosis and treatment. His approach will help us to continue driving clinical research and the development of data-driven therapeutic strategies, which will enable us to contribute positively to the advancement of medical science and offer the most effective and innovative treatments for each individual’.

For his part, Dr. José Antonio López Martín emphasised that he ‘enthusiastically accepts the opportunity to offer my knowledge and experience to the different professionals involved in healthcare decision-making, to continue learning from them, to continue participating in innovation research projects, in order to translate advances in diagnosis and treatment into real-life decisions. Above all, I am a doctor, and I share with Atrys the vocation to serve patients’.